Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interview: Mereo All Set For Key Setrusumab Data

Executive Summary

Although far from a one-product company, data in Q4 will be key to whether the brittle bone drug could become a blockbuster for the UK NASDAQ-listed biotech.

You may also be interested in...



Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

Pfizer Grows In Rare Disease With $810m Dwarfism Company Buy

Pfizer adds to its rare disease portfolio with purchase of Therachon, a Swiss company working in achondroplasia. But whether it can catch up with Biomarin’s Phase III vosoritide is still to be seen.

Ipsen Commercial Chief: Buying Clementia Will Bolster Rare Disease Franchise

Buying Canada-based Clementia is consistent with Ipsen’s strategy to acquire top assets in mid to late stages of development for specialty oncology, neuroscience or rare disease indications, chief commercial officer tells Scrip.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel